AdamM.A., and MillerA.D. (1988). Identification of a signal in a murine retrovirus that is sufficient for packaging of nonretroviral RNA into virions. J. Virol., 62, 3802–3806.
2.
AiutiA., SlavinS., AkerM., et al. (2002). Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science, 296, 2410–2413.
3.
AiutiA., CattaneoF., GalimbertiS., et al. (2009). Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N. Engl. J. Med., 360, 447–458.
4.
AlbrittonL.M., TsengL., ScaddenD., and CunninghamJ.M. (1989). A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell, 57, 659–666.
5.
BattiniJ.L., RaskoJ.E., and MillerA.D. (1999). A human cell-surface receptor for xenotropic and polytropic murine leukemia viruses: possible role in G protein-coupled signal transduction. Proc. Natl. Acad. Sci. USA, 96, 1385–1390.
6.
BenderM.A., PalmerT.D., GelinasR.E., and MillerA.D. (1987). Evidence that the packaging signal of Moloney murine leukemia virus extends into the gag region. J. Virol., 61, 1639–1646.
7.
BlaeseR.M., CulverK.W., MillerA.D., et al. (1995). T lymphocyte-directed gene therapy for ADA− SCID: initial trial results after 4 years. Science, 270, 475–480.
8.
CavazzanaM. (2014). Hematopoietic stem cell gene therapy: progress on the clinical front. Hum. Gene Ther., 25, 165–170.
9.
Cavazzana-CalvoM., Hacein-BeyS., de Saint BasileG., et al. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science, 288, 669–672.
10.
CieriN., MastaglioS., OliveiraG., et al. (2014). Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation. Immunol. Rev., 257, 165–180.
11.
CornettaK., MoenR.C., CulverK., et al. (1990). Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther., 1, 15–30.
12.
CurranT., MillerA.D., ZokasL., and VermaI.M. (1984). Viral and cellular fos proteins: a comparative analysis. Cell, 36, 259–268.
13.
DanosO., and MulliganR.C. (1988). Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. USA, 85, 6460–6464.
14.
DirksC., DuhF.M., RaiS.K., et al. (2002). Mechanism of cell entry and transformation by enzootic nasal tumor virus. J. Virol., 76, 2141–2149.
15.
EglitisM.A., KantoffP., GilboaE., and AndersonW.F. (1985). Gene expression in mice after high efficiency retroviral-mediated gene transfer. Science, 230, 1395–1398.
16.
GasparH.B., CoorayS., GilmourK.C., et al. (2011a). Long-term persistence of a polyclonal T cell repertoire after gene therapy for X-linked severe combined immunodeficiency. Sci. Transl. Med., 3, 97ra79.
17.
GasparH.B., CoorayS., GilmourK.C., et al. (2011b). Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction. Sci. Transl. Med., 3, 97ra80.
18.
Hacein-Bey-AbinaS., Le DeistF., CarlierF., et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med., 346, 1185–1193.
19.
Hacein-Bey-AbinaS., Von KalleC., SchmidtM., et al. (2003). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science, 302, 415–419.
20.
Hacein-Bey-AbinaS., GarrigueA., WangG.P., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest., 118, 3132–3142.
21.
HockR.A., and MillerA.D. (1986). Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells. Nature, 320, 275–277.
22.
HockR.A., MillerA.D., and OsborneW.R. (1989). Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood, 74, 876–881.
23.
HoweS.J., MansourM.R., SchwarzwaelderK., et al. (2008). Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest., 118, 3143–3150.
24.
KantoffP.W., KohnD.B., MitsuyaH., et al. (1986). Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc. Natl. Acad. Sci. USA, 83, 6563–6567.
25.
KavanaughM.P., MillerD.G., ZhangW., et al. (1994). Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc. Natl. Acad. Sci. USA, 91, 7071–7075.
26.
KiemH.P., HeywardS., WinklerA., et al. (1997). Gene transfer into marrow repopulating cells: comparison between amphotropic and gibbon ape leukemia virus pseudotyped retroviral vectors in a competitive repopulation assay in baboons. Blood, 90, 4638–4645.
27.
KimJ.W., ClossE.I., AlbrittonL.M., and CunninghamJ.M. (1991). Transport of cationic amino acids by the mouse ecotropic retrovirus receptor. Nature, 352, 725–728.
28.
KohnD.B., WeinbergK.I., NoltaJ.A., et al. (1995). Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nat. Med., 1, 1017–1023.
29.
KwokW.W., SchueningF., SteadR.B., and MillerA.D. (1986). Retroviral transfer of genes into canine hemopoietic progenitor cells in culture: a model for human gene therapy. Proc. Natl. Acad. Sci. USA, 83, 4552–4555.
30.
MannR., MulliganR.C., and BaltimoreD. (1983). Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell, 33, 153–159.
31.
MarkowitzD., GoffS., and BankA. (1988). Construction and use of a safe and efficient amphotropic packaging cell line. Virology, 167, 400–406.
32.
MillerA.D., and ButtimoreC. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol., 6, 2895–2902.
33.
MillerA.D., and ChenF. (1996). Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. J. Virol., 70, 5564–5571.
34.
MillerD.G., and MillerA.D. (1992). Tunicamycin treatment of CHO cells abrogates multiple blocks to retrovirus infection, one of which is due to a secreted inhibitor. J. Virol., 66, 78–84.
35.
MillerD.G., and MillerA.D. (1994). A family of retroviruses that utilize related phosphate transporters for cell entry. J. Virol., 68, 8270–8276.
36.
MillerA.D., and RosmanG.J. (1989). Improved retroviral vectors for gene transfer and expression. BioTechniques, 7, 980–990.
37.
MillerA.D., JollyD.J., FriedmannT., and VermaI.M. (1983). A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc. Natl. Acad. Sci. USA, 80, 4709–4713.
38.
MillerA.D., CurranT., and VermaI.M. (1984a). c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell, 36, 51–60.
39.
MillerA.D., EcknerR.J., JollyD.J., et al. (1984b). Expression of a retrovirus encoding human HPRT in mice. Science, 225, 630–632.
40.
MillerA.D., OngE.S., RosenfeldM.G., et al. (1984c). Infectious and selectable retrovirus containing an inducible rat growth hormone minigene. Science, 225, 993–998.
41.
MillerA.D., LawM.F., and VermaI.M. (1985). Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol. Cell. Biol., 5, 431–437.
42.
MillerA.D., TrauberD.R., and ButtimoreC. (1986). Factors involved in production of helper virus-free retrovirus vectors. Somat. Cell Mol. Genet., 12, 175–183.
43.
MillerD.G., AdamM.A., and MillerA.D. (1990). Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol. Cell. Biol., 10, 4239–4242.
44.
MillerA.D., GarciaJ.V., von SuhrN., et al. (1991). Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus. J. Virol., 65, 2220–2224.
45.
MillerD.G., EdwardsR.H., and MillerA.D. (1994). Cloning of the cellular receptor for amphotropic murine retroviruses reveals homology to that for gibbon ape leukemia virus. Proc. Natl. Acad. Sci. USA, 91, 78–82.
46.
O'HaraB., JohannS.V., KlingerH.P., et al. (1990). Characterization of a human gene conferring sensitivity to infection by gibbon ape leukemia virus. Cell Growth Differ., 1, 119–127.
47.
OsborneW.R., HockR.A., KalekoM., and MillerA.D. (1990). Long-term expression of human adenosine deaminase in mice after transplantation of bone marrow infected with amphotropic retroviral vectors. Hum. Gene Ther., 1, 31–41.
48.
PalmerT.D., HockR.A., OsborneW.R., and MillerA.D. (1987). Efficient retrovirus-mediated transfer and expression of a human adenosine deaminase gene in diploid skin fibroblasts from an adenosine deaminase-deficient human. Proc. Natl. Acad. Sci. USA, 84, 1055–1059.
49.
PatienceC., TakeuchiY., CossetF.L., and WeissR.A. (1998). Packaging of endogenous retroviral sequences in retroviral vectors produced by murine and human packaging cells. J. Virol., 72, 2671–2676.
50.
RaiS.K., DeMartiniJ.C., and MillerA.D. (2000). Retrovirus vectors bearing jaagsiekte sheep retrovirus Env transduce human cells by using a new receptor localized to chromosome 3p21.3. J. Virol., 74, 4698–4704.
51.
RaiS.K., DuhF.M., VigdorovichV., et al. (2001). Candidate tumor suppressor HYAL2 is a glycosylphosphatidylinositol (GPI)-anchored cell-surface receptor for jaagsiekte sheep retrovirus, the envelope protein of which mediates oncogenic transformation. Proc. Natl. Acad. Sci. USA, 98, 4443–4448.
52.
RosenbergS.A., AebersoldP., CornettaK., et al. (1990). Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med., 323, 570–578.
53.
TailorC.S., NouriA., LeeC.G., et al. (1999). Cloning and characterization of a cell surface receptor for xenotropic and polytropic murine leukemia viruses. Proc. Natl. Acad. Sci. USA, 96, 927–932.
54.
Van HoevenN.S., and MillerA.D. (2005). Improved enzootic nasal tumor virus pseudotype packaging cell lines reveal virus entry requirements in addition to the primary receptor Hyal2. J. Virol., 79, 87–94.
55.
VaughanA.E., MendozaR., ArandaR., et al. (2012). Xpr1 is an atypical G-protein-coupled receptor that mediates xenotropic and polytropic murine retrovirus neurotoxicity. J. Virol., 86, 1661–1669.
56.
WatanabeS., and TeminH.M. (1983). Construction of a helper cell line for avian reticuloendotheliosis virus cloning vectors. Mol. Cell. Biol., 3, 2241–2249.
57.
WolgamotG., RaskoJ.E., and MillerA.D. (1998). Retrovirus packaging cells expressing the Mus dunni endogenous virus envelope facilitate transduction of CHO and primary hematopoietic cells. J. Virol., 72, 10242–10245.
58.
YangY.L., GuoL., XuS., et al. (1999). Receptors for polytropic and xenotropic mouse leukaemia viruses encoded by a single gene at Rmc1. Nat. Genet., 21, 216–219.
